FDA IND clearance for XTX501 is the primary catalyst — watch for dosing initiation in H2 2026 and initial Phase 1 data in H2 2027. The $136M cash runway into Q1 2028 removes near-term financing risk. Monitor potential Series C warrant exercise ($36.2M) and AbbVie milestones (up to $31M through H1 2027) as additional liquidity catalysts.
Price Chart
Executive Summary
Xilio Therapeutics reported Q2 2026 results with collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M (improved from -$15.8M YoY). The key catalyst was FDA clearance of the IND for XTX501, a bispecific PD-1/masked IL-2, enabling Phase 1/2 initiation in H2 2026. Cash runway extends into Q1 2028, supporting pipeline milestones through initial Phase 1 data expected in H2 2027.
Key Facts
- FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2); Phase 1/2 trial initiation expected H2 2026
- Collaboration revenue $18.7M in Q2 2026 vs $8.1M in Q2 2025 (+131% YoY)
- Net loss narrowed to $6.4M in Q2 2026 from $15.8M in Q2 2025
- Cash and equivalents $136.0M as of June 30, 2026; cash runway into Q1 2028
- IND applications for CLDN18.2 and PSMA+STEAP1 TCE programs anticipated in H2 2027
- Up to $36.2M in additional gross proceeds possible if all Series C warrants exercised in H2 2026
Financial Impact
Collaboration revenue $18.7M (Q2 2026) vs $8.1M (Q2 2025); net loss -$6.4M vs -$15.8M; cash $136.0M
Risk Factors
- XTX501 Phase 1/2 clinical trial may fail to demonstrate safety or efficacy
- IND applications for CLDN18.2 and PSMA+STEAP1 programs could be delayed beyond H2 2027
- Cash runway depends on operating plans; higher R&D spend could accelerate burn rate
- Series C warrant exercise is contingent on stock price; may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-345753 |
| Document: xlo-20260812.htm | 0001193125-26-345753 |
| Document: 0001193125-26-345753-index-headers.html | 0001193125-26-345753 |
| Document: 0001193125-26-345753-index.html | 0001193125-26-345753 |
| Document: 0001193125-26-345753.txt | 0001193125-26-345753 |
| 8-K Data (Synthetic) | 0001193125-26-345753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $7.58 (−16.24%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $7.58 (−16.24%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $7.58 (+8.12%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $7.58 (−11.03%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $7.58 (−1.94%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $7.58 (−1.94%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $7.58 (−10.30%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $7.58 (−11.55%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $7.58 (−9.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers